Literature DB >> 1756133

Clinical relevance of myocardial "stunning".

R Bolli1, C J Hartley, R S Rabinovitz.   

Abstract

Experimental studies have demonstrated that myocardium reperfused after reversible ischemia exhibits prolonged depression of contractile function ("stunning"). Despite the multiplicity of clinical situations in which myocardial stunning would be expected to occur, investigation of this phenomenon in humans has been hindered by several major problems, including the limited accuracy of the methods available to measure regional left ventricular function, the inability to quantify regional myocardial blood flow during acute ischemia, the difficulty in establishing with certainty, the beginning and end of an ischemic episode, and the uncontrolled influence of variables (such as preload, afterload, adrenergic tone, and inotropic therapy) that have a major impact on postischemic dysfunction. The main problem is to discern whether a reversible defect of contractility is caused by stunning, silent ischemia, or hibernation (i.e., chronic ischemia). This differential diagnosis requires the simultaneous measurement of regional myocardial function and flow, which thus far has not been generally possible. Despite these limitations, however, numerous clinical observations suggest that stunning does occur in various settings in which the myocardium is exposed to transient ischemia, including coronary angioplasty, exercise-induced angina, angina at rest (unstable or variant), acute myocardial infarction with early reperfusion, open-heart surgery, and cardiac transplantation. Recognition of this entity is important, amongst other reasons, because it is likely to cause significant morbidity and because it is potentially correctable with inotropic therapy or even preventable with antioxidant therapy. In addition, the appreciation of the phenomenon of myocardial stunning should allow the clinician to assess the efficacy of reperfusion therapy with greater accuracy and to recognize that patients should not be denied mechanical revascularization solely because of an abnormal left ventricular wall motion. Perhaps the most intriguing clinical implication of the concept of myocardial stunning is the possibility that in patients who exhibit frequent episodes of ischemia in the same territory, the myocardium may not be able to fully recover between episodes and thus may remain reversibly depressed for prolonged periods of time, or even chronically, which could account for some cases of "ischemic cardiomyopathy." Our understanding of myocardial stunning in humans is still relatively crude and will not significantly improve until studies are performed that measure simultaneously regional myocardial perfusion and function (so that stunning can be differentiated from silent ischemia and hibernation). Future important areas of research should also include the elucidation of whether stunning can become chronic and the evaluation of therapies (such as antioxidant treatments) designed to prevent this contractile abnormality.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1756133     DOI: 10.1007/bf00053548

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  79 in total

1.  Coronary arterial reperfusion. III. Early and late effects on regional myocardial function and dimensions in conscious dogs.

Authors:  P Theroux; J Ross; D Franklin; W S Kemper; S Sasayama
Journal:  Am J Cardiol       Date:  1976-11-04       Impact factor: 2.778

2.  Improvement of myocardial perfusion and left ventricular function after coronary artery bypass grafting in patients with unstable angina.

Authors:  A J Kolibash; J S Goodenow; C A Bush; M R Tetalman; R P Lewis
Journal:  Circulation       Date:  1979-01       Impact factor: 29.690

3.  Evolution of left ventricular function after intracoronary thrombolysis for acute myocardial infarction.

Authors:  W G Schmidt; F H Sheehan; R von Essen; R Uebis; S Effert
Journal:  Am J Cardiol       Date:  1989-03-01       Impact factor: 2.778

4.  Effects of successful percutaneous transluminal coronary angioplasty on global and regional left ventricular function in unstable angina pectoris.

Authors:  P J de Feyter; H Suryapranata; P W Serruys; K Beatt; M van den Brand; P G Hugenholtz
Journal:  Am J Cardiol       Date:  1987-11-01       Impact factor: 2.778

5.  Myocardial metabolism and ventricular function following cold potassium cardioplegia.

Authors:  S E Fremes; R D Weisel; D A Mickle; J Ivanov; M M Madonik; S J Seawright; S Houle; P R McLaughlin; R J Baird
Journal:  J Thorac Cardiovasc Surg       Date:  1985-04       Impact factor: 5.209

6.  Prolonged abnormalities of left ventricular diastolic wall thinning in the "stunned" myocardium in conscious dogs: time course and relation to systolic function.

Authors:  M L Charlat; P G O'Neill; C J Hartley; R Roberts; R Bolli
Journal:  J Am Coll Cardiol       Date:  1989-01       Impact factor: 24.094

7.  A clinical trial of blood and crystalloid cardioplegia.

Authors:  S E Fremes; G T Christakis; R D Weisel; D A Mickle; M M Madonik; J Ivanov; R Harding; S J Seawright; S Houle; P R McLaughlin
Journal:  J Thorac Cardiovasc Surg       Date:  1984-11       Impact factor: 5.209

8.  Inotropic contractile reserve: a useful predictor of increased 5 year survival and improved postoperative left ventricular function in patients with coronary artery disease and reduced ejection fraction.

Authors:  R W Nesto; L H Cohn; J J Collins; J Wynne; L Holman; P F Cohn
Journal:  Am J Cardiol       Date:  1982-07       Impact factor: 2.778

9.  Beta-adrenergic stimulation reverses postischemic myocardial dysfunction without producing subsequent functional deterioration.

Authors:  R Bolli; W X Zhu; M L Myers; C J Hartley; R Roberts
Journal:  Am J Cardiol       Date:  1985-12-01       Impact factor: 2.778

10.  Sequential postoperative assessment of left ventricular performance with gated cardiac blood pool imaging following aortocoronary bypass surgery.

Authors:  L A Reduto; G M Lawrie; J W Reid; H H Whissenand; G P Noon; D Kanon; M E DeBakey; R R Miller
Journal:  Am Heart J       Date:  1981-01       Impact factor: 4.749

View more
  5 in total

Review 1.  Recovery of myocardial function in the hibernating heart.

Authors:  C W Hamm
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

2.  Reperfusion injury after acute myocardial infarction.

Authors:  E D Grech; M J Jackson; D R Ramsdale
Journal:  BMJ       Date:  1995-02-25

3.  PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice.

Authors:  Rui Wang; Lei Xi; Rakesh C Kukreja
Journal:  J Pharmacol Exp Ther       Date:  2017-01-25       Impact factor: 4.030

4.  Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model.

Authors:  Ziyad Mohammed Binsalamah; Arghya Paul; Afshan Afsar Khan; Satya Prakash; Dominique Shum-Tim
Journal:  Int J Nanomedicine       Date:  2011-10-31

Review 5.  Myocardial Viability: From Proof of Concept to Clinical Practice.

Authors:  Aditya Bhat; Gary C H Gan; Timothy C Tan; Chijen Hsu; Alan Robert Denniss
Journal:  Cardiol Res Pract       Date:  2016-05-29       Impact factor: 1.866

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.